研究单位：[1]BeiGene[2]Nanfang Hospital,Southern Medical University Guangzhou, Guangzhou, China, 510515[3]Tongji Hospital of Tongji Medical College Huazhong University of Science Technology Wuhan, Hubei, China华中科技大学同济医学院附属同济医院[4]Jiangsu Province Hospital Nanjing, Jiangsu, China[5]Fudan University Shanghai Cancer Center Shanghai, Shanghai, China
The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma
